ImmunityBio, Inc. (IBRX)
| Market Cap | 6.44B +205.6% |
| Revenue (ttm) | 182.57M +121.2% |
| Net Income | -1.11B |
| EPS | -1.08 |
| Shares Out | 1.06B |
| PE Ratio | n/a |
| Forward PE | n/a |
| Dividend | n/a |
| Ex-Dividend Date | n/a |
| Volume | 11,502,040 |
| Open | 6.11 |
| Previous Close | 6.07 |
| Day's Range | 5.83 - 6.17 |
| 52-Week Range | 1.95 - 12.43 |
| Beta | 0.17 |
| Analysts | Strong Buy |
| Price Target | 14.25 (+135.34%) |
| Earnings Date | Nov 9, 2026 |
About IBRX
ImmunityBio, Inc., a biotechnology company, focuses on innovating, developing, and commercializing next-generation immunotherapies designed to activate the patient’s immune system and deliver durable protection against cancer and infectious diseases. Its platforms for the development of biologic products and product candidates that include cytokine fusion proteins, DNA and vaccine vectors, and cell therapies. The company’s platform has generated first-in-human therapeutic agents that are planned to be studied in clinical trials in liquid and so... [Read more]
Financial Performance
In 2025, ImmunityBio's revenue was $113.29 million, an increase of 668.31% compared to the previous year's $14.75 million. Losses were -$351.40 million, -15.03% less than in 2024.
Financial StatementsAnalyst Summary
According to 4 analysts, the average rating for IBRX stock is "Strong Buy." The 12-month stock price target is $14.25, which is an increase of 135.34% from the latest price.
News
ImmunityBio announces findings from survey of military members with NMIBC
ImmunityBio (IBRX) announced findings from a national survey of military service members and veterans with non-muscle invasive bladder cancer, NMIBC. The survey, conducted by The Harris Poll on behalf...
New U.S. Survey of Military Service Members and Veterans with Non-Muscle Invasive Bladder Cancer Reveals 53% Were Diagnosed at Age 50 or Younger and Barriers to Care
CULVER CITY, Calif.--(BUSINESS WIRE)--ImmunityBio, Inc. (NASDAQ: IBRX), a commercial-stage immunotherapy company, today announced findings from a national survey of military service members and vetera...
ImmunityBio to Participate in UK Investor Conferences During London Life Sciences Week 2026
CULVER CITY, Calif.--(BUSINESS WIRE)--ImmunityBio, Inc. (NASDAQ: IBRX), a commercial-stage immunotherapy company, today announced members of the senior leadership team will speak at the upcoming Jeffe...
ImmunityBio reports Q3 EPS (18c), consensus (8c)
Reports Q3 revenue $48.8M, consensus $59.23M. “The FDA’s recent approval of ANKTIVA plus BCG for papillary-only disease, together with data published in The Journal of Urology showing that more than…
ImmunityBio Reports Label Expansion and Additional Global Approval with Q3 2026 Net Product Revenue of $48.7 Million, Up 53% Year-Over-Year and First Nine Months U.S. Revenue Up 92% to $143.6 Million
CULVER CITY, Calif.--(BUSINESS WIRE)--ImmunityBio, Inc. (NASDAQ: IBRX), a commercial-stage immunotherapy company, today announced continued global expansion, expanded FDA approval, and financial resul...
ImmunityBio Earnings release: Q3 2026
ImmunityBio released its Q3 2026 earnings on November 9, 2026, summarizing the period's financial results.
ImmunityBio Quarterly report: Q3 2026
ImmunityBio has published its Q3 2026 quarterly earnings report on November 9, 2026.
ImmunityBio, Rafa announces Israeli MoH granted approval for Anktiva
ImmunityBio (IBRX) and Rafa Laboratories announced that the Israeli Ministry of Health, MoH, has granted approval for Anktiva, indicated in combination with Bacillus Calmette-Guerin for the treatment ...
ImmunityBio and Rafa Announce Israeli Ministry of Health Approval of ANKTIVA® Plus BCG for BCG-Unresponsive Non-Muscle Invasive Bladder Cancer with Carcinoma in Situ
JERUSALEM & CULVER CITY, Calif.--(BUSINESS WIRE)--ImmunityBio, Inc. (NASDAQ: IBRX) (“ImmunityBio”) and Rafa Laboratories Ltd. (TASE: RAFA) (“Rafa”) today announced that the Israeli Ministry of Health ...
ImmunityBio announces results from rial evaluating intravesical ANKTIVA
ImmunityBio (IBRX) announced positive results from the final analysis of the primary endpoint in Cohort A of QUILT-2.005 a randomized, controlled, registrational trial evaluating intravesical ANKTIVA ...
ImmunityBio Announces ANKTIVA® Plus BCG Meets Primary Endpoint in BCG-Naïve Non-Muscle Invasive Bladder Cancer Randomized QUILT-2.005 Trial
CULVER CITY, Calif.--(BUSINESS WIRE)--ImmunityBio, Inc. (NASDAQ: IBRX), a commercial-stage immunotherapy company, today announced positive results from the final analysis of the primary endpoint in Co...
ImmunityBio announces first patients in Europe treated with ANKTIVA
ImmunityBio (IBRX) announced that the first patients in Europe received treatment with ANKTIVA in combination with Bacillus Calmette-Guerin, BCG, for BCG-unresponsive non-muscle invasive bladder cance...
ImmunityBio Announces First Patients in Europe Treated with ANKTIVA® Plus BCG for BCG-unresponsive Non-Muscle Invasive Bladder Cancer with Carcinoma in Situ
CULVER CITY, Calif. & DUBLIN--(BUSINESS WIRE)--ImmunityBio, Inc. (NASDAQ: IBRX), a commercial-stage immunotherapy company, today announced that the first patients in Europe received treatment with ANK...
ImmunityBio announces database lock for Cohort A of QUILT-2.005
ImmunityBio (IBRX) announced completion of the database lock for Cohort A of QUILT-2.005, its randomized, controlled, registrational trial evaluating ANKTIVA in combination with Bacillus Calmette-Guer...
ImmunityBio Announces Database Lock for Registrational Trial of Locally Delivered, Chemotherapy-Free ANKTIVA® Plus BCG in BCG-Naïve Non-Muscle Invasive Bladder Cancer
CULVER CITY, Calif.--(BUSINESS WIRE)--ImmunityBio, Inc. (NASDAQ: IBRX), an immunotherapy company, today announced completion of the database lock for Cohort A of QUILT-2.005 (NCT02138734), its randomi...
ImmunityBio announces publication of long-term data from QUILT-3.032 study
ImmunityBio (IBRX) announced the publication of long-term data from the Phase 2/3 QUILT-3.032 study in the Journal of Urology. The study evaluated ANKTIVA in combination with Bacillus Calmette-Guerin ...
ImmunityBio Reports Phase 3 Data Showing 84% Cystectomy Avoidance at Three Years and Complete Responses Beyond 53 Months with ANKTIVA® Plus BCG in BCG-Unresponsive NMIBC With CIS, With or Without Papillary Tumors
CULVER CITY, Calif.--(BUSINESS WIRE)--ImmunityBio, Inc. (NASDAQ: IBRX), a commercial-stage immunotherapy company, today announced the publication of long-term data from the Phase 2/3 QUILT-3.032 study...
ImmunityBio price target raised to $14 from $12 at Jefferies
Jefferies raised the firm’s price target on ImmunityBio (IBRX) to $14 from $12 and keeps a Buy rating on the shares after the FDA expanded the approved indication for Anktiva…
ImmunityBio says FDA expands approval indication for ANKTIVA-BCG combo
ImmunityBio (IBRX) announced that the U.S. Food and Drug Administration has expanded the approved indication for ANKTIVA in combination with Bacillus Calmette-Guerin to include patients with BCG-unres...
FDA Expands ANKTIVA® Approval for BCG-Unresponsive Non-Muscle-Invasive Bladder Cancer to Cover Both Papillary and CIS Disease
CULVER CITY, Calif.--(BUSINESS WIRE)--ImmunityBio, Inc. (NASDAQ: IBRX), a commercial-stage immunotherapy company, today announced that the U.S. Food and Drug Administration (FDA) has expanded the appr...
ImmunityBio price target raised to $16 from $12 at Piper Sandler
Piper Sandler raised the firm’s price target on ImmunityBio (IBRX) to $16 from $12 and keeps an Overweight rating on the shares.
ImmunityBio to Participate in the Piper Sandler Virtual Oncology Symposium
CULVER CITY, Calif.--(BUSINESS WIRE)--ImmunityBio, Inc. (NASDAQ: IBRX), a commercial-stage immunotherapy company, today announced that Dr. Patrick Soon-Shiong, its Founder, Executive Chairman and Glob...